Institut National de la Santé et de la Recherche Médicale (INSERM)

Rodolphe ID petite

Prof. Rodolphe Thiébaut


INSERM, U897, 146 rue Léo Saignat, 33076 Bordeaux, France


Rodolphe Thiébaut has been trained as a medical doctor specialized in Public Health. He did a PhD in Biostatistics at Bordeaux University in France. He started his research carrier at the Inserm as a researcher in 2002 and research director between 2010 and 2013. He has been research fellow in the Immuniology division of the Institute of Child Health in 2007. He is now deputy head of the INSERM U897 “Epidemiology & Biostatistics” research centre and professor in Public Health / Biostatistics at the University of Bordeaux. He is co-coordinator of the Epidemiology specialty for the second year of the Master at ISPED (Institut de Santé Publique d'Epidémiologie et de Dévelopement). He is leading a research group (SISTM-Statistics in Systems Biology and Translational Medicine) devoted to the design and analysis of clinical trials mainly in HIV immunology through the French Vaccine Research Institute. This group, which is embedded in the Inserm U897 research centre, has been regognized as an INRIA project team since January 2015. Its translational research starts with immunological questions and end with the development of statistical methods for the collection and analysis of high-dimensional datasets generated in this domain. He is leading the “Biostatistics/Bioinformatics” division of the Vaccine Research Institute and is in charge of the clinical trial unit of the Bordeaux University Hospital.
Rodolphe Thiebaut is the author/co-author of more than 160 publications in peer-reviewed journals including New England Journal, Lancet, AIDS, Journal of Immunology, Biometrucs, Statistics in Medicine, Plos Computational Biology.


Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen)

Macaya DMacaya Douoguih

Project leader, WP2 co-leader


Macaya Douoguih is a medical doctor with over 8 years experience in clinical development of viral vectored vaccines and had led clinical programs for mainly adenovirus-based vaccine candidates for TB, malaria, RSV and Ebola as well as influenza monoclonal antibodies. She obtained her M.D. degree from the University of Wisconsin-Madison, Wisconsin (US), and her M.P.H. from Johns Hopkins Bloomberg School of Public Health, Maryland (US), and maintains board certifications in Family Medicine and Preventive Medicine. Prior to working in the pharmaceutical industry, she worked as a Medical Officer at the NIH overseeing clinical and epidemiologic research focused on infectious diseases such as HIV, Malaria, TB, as well as therapeutic interventions to reduce perinatal mortality in low-income settings.

Institut National de la Santé et de la Recherche Médicale (INSERM)

ottaviDr Anton Ottavi

International project coordinator

INSERM, U897146 rue Léo Saignat, 33076 Bordeaux, France





lelievreProf. Jean-Daniel LeLièvre

INSERM, Vaccine Research Institute (VRI), Hôpital Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny, 94010 Créteil cedex

Jean-Daniel Lelièvre is a professor in Immunology at University Paris Est Créteil, France. He heads the department of clinical immunology and infectious diseases, and an INSERM team dedicated to the study of HIV pathophysiology. He is in charge of the clinical core of the VRI, a French consortium whose mission is to conduct research to develop an effective vaccine against HIV. His role in this consortium is to develop new vaccines trials but also to decipher the motivations of healthy volunteers or patients to participate in clinical trials. Pr JD Lelièvre is an investigator in several clinical trials in the field of immune-based therapies of HIV infection and HIV vaccine. He is also in charge of work packages of different European projects on HIV. He is a member of the Social Sciences and Clinical Trial committees of the ANRS and of the scientific committee of Sidaction.

lacabaratzDr Christine Lacabaratz
WP3 Co-leader

INSERM, Vaccine Research Institute (VRI)Hôpital Henri Mondor, 51 avenue du Maréchal de Lattre de Tassigny, 94010 Créteil cedex, France

Christine Lacabaratz’s, PhD, area of expertise is cellular immunity in HIV infection. She has contributed to describing the evolution of CD8 responses in a large cohort of acutely HIV- infected patients and in HIV controllers. She heads the immunomonitoring platform of the VRI.


raoulDr Hervé Raoul
WP4 co-leader

INSERM, Laboratoire P4 Jean Mérieux21 Avenue Tony Garnier, 69007 Lyon, France

Hervé Raoul, PhD, was appointed Director of the French BSL4 Inserm Jean Mérieux laboratory in Lyon in 2005. He has reorganized the laboratory to open the infrastructure to national and international research teams. He has also developed diagnosis activities at national level but also through initiation of collaboration with foreign countries in Eastern Europe, central Asia and Asia. He is also the coordinator of the ESFRI BMS research infrastructure ERINHA project dedicated to the creation of a Pan-European BSL4 infrastructure. He has been vice-president of the Scientific Board of Center for Emerging Infectious Diseases (CEID), Wuhan, P.R. of China, since 2008; Member of the Scientific and Strategic Orientation Committee (COSS) of the Institute for Experimentation in Animal Infectiology (IEIA), INRA, France; Member of the Group of High-containment Laboratory Directors (GOHLD); Member of the Board of Directors of the pole of competitiveness TRIMATEC and expert for the French Ministry. He coordinates the REACTION! project carrying out phase IIb trials on another candidate Ebola vaccine.


Prof. Philippe Van de Perre
INSERM, U 1058 - mixte avec Université de Montpellier
Research Centre on Chronic Infections, UFR de Pharmacie, BP 14491, Bât. I, 1er étage, 15 avenue Charles Flahault, 34093 MONTPELLIER Cedex 5, France 

Pr Philippe Van de Perre is Professor of medicine (virology & bacteriology) at the University Montpellier 1, Head of Department of Bacteriology-Virology at Montpellier University Teaching Hospital, Vice President of the UTH directorate and Director of INSERM Unit 1058.


richertDr Laura Richert

WP2 Co-leader

Unité de Soutien Méthodologique à la Recherche Clinique et Epidémiologique du CHU de Bordeaux (USMR) / Clinical Epidemiology Unit
Service d'Information Médicale, Pôle de Santé Publique, Université Bordeaux Segalen, Case 75, 146 rue Léo Saignat, 33076 Bordeaux cedex, France

Laura Richert, MD, PhD, is a clinical epidemiologist at INSERM U897 and co-coordinator of the CIC1401/EUCLID international clinical trials platform.


EllenEllen Hubin

Project Manager


Ellen Hubin graduated as a bio-engineer at the Free University of Brussels, Belgium, and obtained her PhD degree after performing research on Alzheimer’s disease mechanisms. She continued her research in the field of neuroscience and managed multiple projects during her postdoc at the University of Twente, The Netherlands. Ellen is now working as a Life Science project manager/consultant at CMAST. In April 2015, she joined the EBOVAC 1 and 2 project management teams as a contractor of Janssen. 

no pictureNora Bachmayer

WP3 co-leader


photo M.van Speybroeck

Michel Van Speybroeck

WP5 Leader

Janssen, Belgium

IT Director R&D for Infectious Diseases and Vaccines in Leiden (NL) and Beerse (BE) with an interest in medical informatics. Michel graduated as bioengineer in chemistry and biochemistry from the University of Ghent.



London School of Hygiene & Tropical Medicine (LSHTM)

watson jonesDr. Deborah Watson-Jones

in charge of LSHTM Phase 2 trials in African countries for EBOVAC2

London School of Hygiene and Tropical MedicineKeppel Street, London WC1E 7HT, United Kingdom

Deborah Watson Jones is reader in Clinical Epidemiology & International Health, Coordinator of HPV vaccine research in Mwanza, Tanzania and member of UK Government Expert panel on clinical trials for a prime boost Ebola vaccine regimen. She is part of the following working groups: LSHTM Ebola Task Force, GAVI Independent Review Committee (2012-13); LSHTM Clinical Trials sub-Committee; Steering Committee for WHO Cervical Cancer Control (C4-GEP); Technical Advisory Groups Tanzania National Cervical Cancer Control Programme.


University of Oxford (UOXF)

no pictureProf. Andrew Pollard

University of OxfordUniversity Offices, Wellington Square, Oxford OX1 2JD, United Kingdom

Andrew J. Pollard is Professor of Paediatric Infection and Immunity at the University of Oxford, Director of the Oxford Vaccine Group, James Martin Senior Fellow, Jenner Institute Investigator, Fellow of the Infectious Disease Society of America, Fellow of St Cross College and Honorary Consultant Paediatrician at the Children’s Hospital, Oxford, UK. He obtained his medical degree at St Bartholomew’s Hospital Medical School, University of London in 1989 and trained in Paediatrics at Birmingham Children’s Hospital, UK, specialising in Paediatric Infectious Diseases at St Mary’s Hospital, London, UK and at British Columbia Children’s Hospital, Vancouver, Canada. He obtained his PhD at St Mary’s Hospital, London, UK in 1999 studying immunity to Neisseria meningitidis in children and proceeded to work on anti-bacterial innate immune responses in children in Canada before returning to his current position at the University of Oxford, UK in 2001. He chaired the UK’s NICE meningitis guidelines development group, the NICE topic expert group developing quality standards for management of meningitis and meningococcal septicaemia. He chairs the UK Department of Health’s Joint Committee on Vaccination and Immunisation and the European Medicines Agency scientific advisory group on vaccines. His research includes the design, development and clinical evaluation of vaccines including those for meningococcal disease and enteric fever and leads studies using a human challenge model of (para)typhoid. He also runs surveillance for invasive bacterial diseases and studies the impact of pneumococcal vaccines in children in Nepal. He is the clinical lead for children for the Oxford Academic Health Science Network, the children’s lead for the NIHR Thames Valley Clinical Research Network and is the vaccines theme co-lead for the NIHR Oxford Biomedical Research Centre. He received the 2013 Bill Marshall Award of the European Society for Paediatric Infectious Disease. He directs the postgraduate diploma and MSc in Paediatric Infectious Disease for Oxford University and has led the annual Oxford course “Hot topics in infection and immunity in children” as a partnership with ESPID since 2002. He has supervised 23 PhD students and his publications include over 300 manuscripts and books on various topics in paediatrics, infectious diseases, and high altitude medicine. He is leading a Wellcome Trust award to study enteric fever in Nepal, Bangladesh and Malawi which will be initiated in April 2015.

Le Centre Muraz (CM)

medaProf. Nicolas Meda

CENTRE MURAZ, Burkina Faso

Nicolas Meda, MD, PhD, HDR (Research Professorship), medical epidemiologist and senior health research scientist, is the Director-General of Centre MURAZ, a Health Research Institute in Burkina Faso within the Ministry of Health. Centre MURAZ acts as the National Reference Laboratory for Viral Haemorrhagic Fevers, including Ebola Virus Disease in Burkina Faso. Dr. MEDA is also the country coordinator of French National Agency for AIDS Research (ANRS) activities in Burkina Faso. He is Professor of epidemiology and public health at the University of Ouagadougou. His major areas of research expertise include Epidemiological surveillance and studies, Mother-to-Child Transmission of HIV and its prevention, Reproductive Health (safe motherhood) and Research ethics. He has conducted multi-centre clinical trials in the area of Mother-to-Child Transmission of HIV and epidemiological studies among vulnerable populations for HIV like young people, prisoners, and commercial sex workers, urban and rural women. He is the national Principal Investigator for various HIV and maternal and child health international collaborative research projects funded by ANRS, DFID, EU, EDCTP and a former member of UNAIDS/WHO Monitoring & Evaluation Reference Group. He is the author of more than 150 articles published in international journals, reviewer and member of editorial boards for a number of different international journals, consultant for different UN system agencies and member of several national and international public health programmes steering committees, scientific review committees and networks.


Inserm Transfert (IT)
no picture

Sinéad Quigley

Project Manager, WP6 leader

Inserm Transfert
CH du Vinatier, Bât. 452B, 95 Bd Pinel, 69500 Bron, France

Sinéad graduated with a Masters in Management of Development projects in the areas of health, education and training from the University of Paris, Panthéon-Sorbonne. After an internship at the OECD health division, she worked as a European project manager at the Asia Network of the CNRS. She then joined France Expertise Internationale where she was involved in setting up projects in several areas including HIV. She managed a UNITAID-funded project to improve access to viral load testing in African countries and participated in the 5% Initiative-AIDS, TB and Malaria. She has been a Project manager at Inserm Transfert since August 2014.



  • 23 April 2019

    An Ebovac2 poster was selected among 13 out of approx. 2 500 posters on the top rated of the ECCMID 2019. To view the poster, please, click here. Congratulations to the authors!

  • 24 September 2018

    The 7th newsletter is available here. This issue announces Ebovac2 4th annual meeting in Nairobi (Kenya) in January 2019. 

  • 17 January 2018

    Clinical Trial Training - Bobo Dioulasso, BURKINA FASO, 23-26 January, 2018. For more information

  • 12 September 2017

    The 3rd EBOVAC1/2 Annual meeting will be held in Amsteram, the Netherlands 8-10 January 2018. Participants include consortium members and representatives of sites where the project clinical trials are being carried out.

  • 15 May 2017

    Based on final Phase 1 data published in JAMA: The Journal of the American Medical Association, the prime-boost Ebola vaccine regimen induced an antibody response that persisted in 100 percent of healthy volunteers to at least 1 year following vaccination. The results are from the EBOVAC1 study EBL1001 conducted by the Oxford Vaccine Group in the UK.

  • 15 May 2017

    Victoria Derbyshire reporter Catrin Nye went to visit the Oxford Vaccine Group looking for volunteers who participated in the EBL2001 study. Prof. Andrew Pollard (Professor of Paediatric Infection and Immunity and Oxford Vaccine Group PI for EBOVAC1 and EBOVAC2 ) and study volunteers were interviewed.Watch here :

More news
  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research